3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Gastrointestinal
4
Thoracic
3
Dermatologic
2
Tumor-Agnostic
1
Other solid neoplasm
1
Lymphoid
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Advanced Solid Tumors
1
Interventions
pembrolizumab
14
Injections
13
Specimen Handling
9
Pemetrexed
9
tislelizumab
8
Carboplatin
8
Interviews as Topic
7
Cisplatin
7
atezolizumab
6
fludarabine
5
Educational Status
5
Cyclophosphamide
5
Bevacizumab
5
Standard of Care
4
Practice Guidelines as Topic
4
Platinum
4
Nivolumab
4
Methods
4
Fluorouracil
4
Early Intervention, Educational
4
Capecitabine
4
Biopsy
4
Trastuzumab
3
Paclitaxel
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune Checkpoint Inhibitors
×
Other solid neoplasm
×
30 days
×
Clear all
NCT06819735
2026-05-06
DOMISOL
Domain Therapeutics SA
Phase 1/2
Recruiting
125 enrolled